EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Why Do Pharma Construction Projects Need Cost Certainty | Linesight | ISPE Singapore 2026 | Pharma Focus Asia
Associate Director, Project Controls, Linesight
Stephanie Ledwidge is an experienced project controls and cost management professional with expertise across the life sciences and pharmaceutical sectors She currently serves as Associate Director Project Controls at Linesight in Singapore Her experience spans project controls cost engineering project coordination and project delivery with previous roles supporting organisations including CSL Behr...
Articles
The Role of Artificial Intelligence in Advancing Pharmacovigilance Systems
Pharmacovigilance refers to the detection assessment monitoring and prevention of adverse drug reactions It is an essential part of scientific research and healthcare and has paramount importance in monitoring the safety and effectiveness of pharmaceuticals Pharmacovigilance can be traced back to the th century and it has grown rapidly since then By the end of the th century pharmacovigilance
Research Insights
Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine
Abstract Background Inflammatory breast cancer IBC is a rare aggressive form of breast cancer associated with HER amplification with high risk of metastasis and an estimated median survival of y We performed an openlabel singlearm phase II clinical trial ClinicalTrialsgov NCT to in
Case Studies
Case Study: A Simple And Sensitive Method To Analyze Genotoxic Impurityhydrazine In Pharmaceutical Materials
Abstract Hydrazine NH is a known genotoxic impurity that typically needs to be controlled down to low ppm level in pharmaceutical development Hydrazine however is a challenging molecule to analyze using conventional analytical techniques due to its physical and chemical properties eg lack of chromophore absence of any carbon atom low molecular weigh
Techno Trends
The University of Manchester Unveils Ground Breaking Gene Therapy Trial for Hunter Syndrome
The University of Manchester has introduced an breakthrough in gene therapy targeting young children diagnosed with Hunter syndrome a rare and devastating lysosomal storage disorder
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
The Rapidly Evolving Landscape of Cancer Therapeutics
Rajesh Kumar is an Assistant Professor of Pharmaceutical Sciences at Kerala University of Health Sciences, India. He has been teaching Diploma, Bachelor, and Doctor of Pharmacy students for several years and is actively involved in research. He has authored more than 19 papers and is a reviewer for Bentham Science Publishers. His research includes applying the principles of pharmaceutical sciences, omics technologies, computational biology, and bioinformatics in the broad areas of cancer research, ethnopharmacology, drug delivery, targeting, and formulations.
Seetha Harilal is an Assistant Professor of Pharmacology at Kerala University of Health Sciences, India. She has several years of experience in teaching Diploma, Bachelor, and Doctor of Pharmacy students and is actively pursuing research. She has authored more than 22 papers and is a manuscript reviewer for Bentham Science Publishers, Frontiers in Public Health, Frontiers in Medicine, and Archives of Medical Research (Elsevier). Her research includes the diverse areas of pharmacology and therapeutics, phytopharmaceuticals, cancer research, neurological disorders, and the application of omics technologies, computational pharmacology, and bioinformatics.
Analysis of Blood Microbiota Compositionin Cardiovascular Disease Patients
Dr. Ikram Khan, the first author of the Article, Studying Medical Microbiology in Lanzhou University China as a PhD student, and working on blood microbial Ecology and their association with cardiovascular disease. In March 2022, we published two Articles on this work. Email: ikram2018@lzu.edu.cn
Assistant Professor Imran Khan, 2nd Author of this article, Supervises BS(Hons) students and is engaged in the teaching and research of Bacteriology, Nano-medicine, and Molecular Biology. Presently working as, a member of Quality Enhancement Cell at Xcito School of Nursing and Allied Health Sciences Pakistan. Email:Imran.mic727@gmail.com
Professor Zhou Jianye, is also Co-supervisor of this study, and supervises Master students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology at School of Northwest Minzu University”.Email: 14092785@qq.com
Professor Xie Ping, supervises Master and PhD students.She has long been engaged in the research of cardiovascular disease pathogenesis and drug prevention. Her current status is “Director of Cardiovascular Center of Gansu Provincial Hospital”.
Professor Li Zhiqiang, is a Co-supervisor of this study, and supervises Master and PhD students. He Engaged in the Teaching and Research of Stomatology and Microbial Ecology. His current status is “Director of graduate School of Northwest Minzu University”. Email: Lizhiqiang6767@163.com
Professor An Lizhe, supervise this work as a First Supervisor. He supervises PhD and doctoral students, and engaged in the Teaching and Research of Molecular Biology, Environmental Botany and Ecology. Currently working as, a President and Deputy Secretary of the Party Committee of Beijing Forestry University. Email: yxlzq@xbmu.edu.cn
Dr. Zhang Xiaowei is a professor, chief physician, director of the second ward of cardiovascular medicine, and deputy director of the Science and Technology Department. He has completed projects such as epidemiological investigation and prevention plan research of hypertension in Gansu Province and has published many SCI and CSCD papers, and currently undertakes 1st national natural science foundation, 2nd provincial natural science foundations, and 1st municipal science foundation.
The Value in Decolonising Drug Discovery
Jesse Grey Eagle (Oglala Lakota) is the founder of Indigenous Futures OS and a governance designer for Tribal nations. He works at the nexus of ethical data, AI sovereignty, and long-view institutional systems, advocating for partnership architectures that move beyond extraction.
Sabah Ul-Hasan is a Ph.D. scientist with over 15 years of practice in the life sciences. An Indian-Pakistani American based in Albuquerque (New Mexico), Dr. Ul-Hasan centers on ethical data practices that bridge science with community-based knowledge systems.
Synbiotics in Metabolic Health
Dr. Neeraj Mishra is working as Professor and Head, Department of Pharmaceutics, in Amity Institute of Pharmacy, Gwalior since July 2019. He has around twenty years of teaching and research experience. He has more than 100 publications of International and National repute in recent concepts of novel drug delivery systems, localised drug delivery, targeted and controlled drug delivery of nanocarriers/ microparticles for the treatment of breast, colon cancer, and neurodegenerative disorders. Dr. Mishra more than 3700 citations with h- index 32. The total cumulative Impact Factor of his published papers is more than 300 (as per SCOPUS). He has also written 15 Books and 30 book chapters in Elsevier, Bentham, Springer and Wiley Publication etc. He has also been granted 3 international patents and 2 Indian patents. Dr. Mishra is recipient of “Distinguished Professor Award” 2019 from DST-NSTMIS, SPAICS, Indore, and M.P. in September 2019. Dr. Mishra has received the “Distinguished Professor Award '' 2021 from Indian Pharmaceutical Association, MP State Branch, Indore. Dr Mishra has received Best Academician Award in the Indian Pharmacy Graduate Association, M.P. State International Conference held on 06th May 2023 at DAVV Auditorium, Indore, India.
Dr. Devyani Rajput is working as an Assistant Professor, Department of Pharmacognosy, in Amity Institute of Pharmacy, Gwalior since Jan 2024. She has around seven years of research experience. Her expertise includes nanotechnology, phytomedicine, and advanced drug delivery systems, with notable contributions to cancer research. She has participated in various national and international conferences, published impactful research, and received prestigious awards, including the BEST SCHOLAR AWARD 2023. She has more than 150 citations with h- index 3. She has received the CSIR travel Grant in April 2024 for presenting her research work in Istanbul University.
Harnessing Artificial Intelligence
Anita-Ioana Visan, a Scientific Researcher 2nd degree, at the Laser-Surface-Plasma Interactions (LSPI) Laboratory, Lasers Department, National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, is an expert in nanopowders synthesis and characterisation, as well as thin coatings of calcium phosphates, biopolymers, flavonoids, antibiotics, and antimicrobial peptides synthesized by Pulsed Laser Deposition, Matrix Assisted Pulsed Laser Evaporation, and Combinatorial-MAPLE. Moreover, she has a profound knowledge of thin films characterisation methods, including UV-Vis, FTIR, XRD, SEM, AFM, fluorescence microscopy, electrochemical, magnetic induction, biodegradation, and antimicrobial tests. With her current research focusing on the cutting-edge fields of artificial neural networks, drug repurposing, and pharmaceutical AI, she is paving the way for innovative solutions that have the potential to revolutionise the field of medicine. If you would like to contact her, please use the following email address: anita.visan@inflpr.ro. Furthermore, you can find her professional profile at https://orcid.org/0000-0003-0539-4160.
Irina Negut is a Scientific Researcher 2nd degree, at the National Institute for Lasers, Plasma and Radiation Physics (INFLPR) in Magurele, Romania. She has important experience in fabricating and investigating the characteristics and (bio) functionality of nano-sized/-structured materials (including composite and hybrid particles, thin films and laser-processed coatings). Her research activity includes coating synthesis by laser-assisted techniques. She is also highly experienced in evaluating the compositional and microstructural aspects of nanomaterials and coatings, but also in assessing their optical, thermal, electrical, and electrochemical properties. If you would like to contact her, please use the following email address: negut.irina@inflpr.ro. Her professional profile can be found at https://orcid.org/0000-0003-4038-7548.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement